Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-04-15

FDA Approved: COPAXONE — Supplemental Application (Teva Neuroscience, Inc.)

View source ↗

Summary

FDA approves a supplemental application for COPAXONE (glatiramer acetate) by Teva Neuroscience, expanding the labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • COPAXONE (GLATIRAMER ACETATE)

Snippet

SUPPL AP for COPAXONE (GLATIRAMER ACETATE)